| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6123125 | Journal of Infection | 2014 | 11 Pages |
â¢We analyzed the effect of prophylaxis on the epidemiology of bacteremia in HSCT.â¢Prophylaxis was associated with decreased incidence of bacteremia up to Day 100.â¢Vancomycin was protective against streptococcal and staphylococcal bacteremia.â¢Fluoroquinolone was protective against Gram-negative rod (GNR) bacteremia.â¢Prophylaxis did not impact incidence of VRE and resistant GNR.
SummaryBackgroundWe analyzed the effect of peri-transplant prophylaxis on the epidemiology of bacteremia in a 12-year contemporary cohort of allogeneic HSCT recipients at our center.MethodsThis was an observational study of 1052 consecutive adult HSCT from 2000 to 2011. Formal prophylaxis with vancomycin only, fluoroquinolone (FQ) only, or vancomycin + FQ was implemented in 2006. The cumulative incidence of day 100 bacteremia was compared between the Early Period (2000-2005) and the Recent Period (2006-2011). Predictors for pre-engraftment bacteremia were analyzed with Cox-proportional hazard models in a subcohort of 821 HSCT who received myeloablative or reduced intensity conditioning (MA/RIC).ResultsThe incidence of bacteremia decreased in the Recent Period (32% vs 27%; P = 0.002), whereas the rates of resistance in gram-negative rods (GNR) and vancomycin-resistant enterococci (VRE) were similar between the two Periods (P values are not statistically significant.) In multivariate analyses, prophylaxis with vancomycin only or vancomycin + FQ was protective (HR = 0.5; CI = 0.30-0.72) and (HR = 0.3; CI = 0.12-0.52, P < 0.01). Vancomycin or vancomycin + FQ eliminated viridans streptococcal bacteremia (VSB); vancomycin + FQ decreased GNR bacteremia (HR = 0.35; CI = 0.15-0.85).ConclusionsVancomycin-based prophylaxis peri-transplant in MA/RIC HSCT was associated with elimination of VSB and may be considered at centers with high incidence of this infection.
